ALAN SWANN to Alzheimer Disease
This is a "connection" page, showing publications ALAN SWANN has written about Alzheimer Disease.
Connection Strength
0.105
-
Long-term outpatient treatment of senile dementia with oral physostigmine. J Clin Psychiatry. 1988 Oct; 49(10):400-4.
Score: 0.041
-
Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology (Berl). 1985; 87(2):147-51.
Score: 0.032
-
The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry. 2001 May; 16(5):499-503.
Score: 0.024
-
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005 Apr 16; 330(7496):874.
Score: 0.008